Core Insights - Inspire Medical Systems, Inc. (NYSE:INSP) has recently experienced significant stock performance, reaching a three-month high due to bullish coverage and a price target upgrade from Wolfe Research [1][2] - Wolfe Research upgraded Inspire Medical's rating from "peer perform" to "outperform" with a new price target of $180, indicating a 38% upside potential from its latest closing price [2] - The revision in price target is attributed to updates in Medicare's outpatient payment structure, which will increase payments for Inspire Medical procedures from $30,000 to $45,000 [3] Financial Performance - Inspire Medical reported a net income of $9.9 million for Q3, reflecting a 46% decline from $18.5 million in the same period last year [4] - Despite the decline in net income, revenues increased by 10.5% year-on-year to $224.5 million, driven by a 9% growth in US operations, amounting to $214.4 million [4] - For the full year 2025, the company maintains its revenue guidance of $900 million to $910 million, implying a year-on-year growth of 12 to 13% [5]